Vasomedical gets Medicare to review counterpulsation therapy
This article was originally published in Clinica
Executive Summary
Medicare has agreed to reconsider its current coverage policy for counterpulsation therapy at the request of device manufacturer Vasomedical. The federal health plan for the elderly and disabled has been paying to treat patients diagnosed with disabling angina since 1999, but now will consider paying to also treat patients with less severe angina or with early or moderate congestive heart failure (CHF) as well.